AI assistant
Rekor Systems, Inc. — Director's Dealing 2018
Dec 11, 2018
33647_dirs_2018-12-11_d7642469-f564-4648-aa6b-75dff3ea83b1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Novume Solutions, Inc. (NVMM)
CIK: 0001697851
Period of Report: 2018-12-10
Reporting Person: BERMAN ROBERT ALAN (N/A)
Reporting Person: Avon Road Partners, L.P. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-10 | Common Stock | A | 2725836 | $.5155 | Acquired | 2869083 | Indirect |
| 2018-12-10 | Common Stock | A | 1593021 | $.5155 | Acquired | 4462104 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-10 | Avon Option to Purchase (McCarthy) | $.5155 | X | 2725836 | Disposed | 2019-03-21 | Common Stock (2725836) | Indirect |
| 2018-12-10 | Avon Option to Purchase (Nathan) | $.5155 | X | 1593021 | Disposed | 2019-03-21 | Common Stock (1593021) | Indirect |
Footnotes
F1: The shares were acquired pursuant to Avon Road Partners, L.P.'s ("Avon Road") exercise of options (the "Options") to purchase shares of common stock of Novume Solutions, Inc. ("Novume") from James McCarthy and Richard Nathan. The Options were granted to Avon Road pursuant to the Option Agreement, dated March 16, 2016, amended as of September 7, 2017, by and among James McCarthy and Richard Nathan as grantors and Avon Road as the option holder (the "Option Agreement").
F2: Represents shares acquired by Avon Road, of which Mr. Berman is the general partner. As a result, Mr. Berman may be deemed to beneficially own the Issuer's securities held by Avon Road.
F3: Pursuant to the terms of the Option Agreement, Avon Road paid the stockholders $10,000 each (a total of $20,000) for the right to purchase, on a simultaneous and pro-rata basis, up to 4,318,857 shares of Novume's common stock owned by the shareholders at a purchase price of $0.5155 per share.